Skip to Content

Milestone Pharmaceuticals Inc MIST

Morningstar Rating

Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024

GlobeNewswire May 2, 2024 12:00pm
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

GlobeNewswire Apr 17, 2024 12:00pm
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

GlobeNewswire Apr 8, 2024 3:36pm
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

GlobeNewswire Apr 3, 2024 12:00pm
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

GlobeNewswire Apr 1, 2024 12:00pm
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia

GlobeNewswire Mar 28, 2024 11:00am
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

GlobeNewswire Mar 21, 2024 11:14am
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

GlobeNewswire Feb 29, 2024 9:01pm
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

GlobeNewswire Feb 29, 2024 12:00pm
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

GlobeNewswire Feb 28, 2024 9:37pm
Milestone Pharma Shares Rise 25% After Plans to Resubmit Etripamil NDA

Global News Select Feb 26, 2024 3:42pm
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT

GlobeNewswire Feb 26, 2024 12:00pm
Milestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDA

Global News Select Dec 26, 2023 1:39pm
Milestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File Letter

Global News Select Dec 26, 2023 12:42pm

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.